Vitrakvi Dosage
Generic name: LAROTRECTINIB 25mg
Dosage form: capsules, oral solution
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 30, 2025.
Patient Selection
Select patients for treatment with VITRAKVI based on the presence of a NTRK gene fusion in tumor specimens.
In patients with secretory breast cancer, mammary analogue secretory cancer (MASC), congenital mesoblastic nephroma (CMN), or infantile fibrosarcoma, consider treatment without confirmation of NTRK rearrangements in tumor specimens.
Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics.
Recommended Dosage
Dosage Modifications for Adverse Reactions
For Grade 2 and higher liver function test abnormalities, refer to Section 2.4, Table 2, Dosage Modifications for Hepatotoxicity.
For all other Grade 3 or 4 adverse reactions:
- Withhold VITRAKVI until adverse reaction resolves or improves to baseline or Grade 1. Resume at the next dosage modification if resolution occurs within 4 weeks.
- Permanently discontinue VITRAKVI if an adverse reaction does not resolve within 4 weeks.
The recommended dosage reductions for VITRAKVI for adverse reactions are provided in Table 1.
Dosage Reduction | Adult and Pediatric Patients with Body Surface Area of 1 m2 or Greater | Pediatric Patients with Body Surface Area Less Than 1 m2 |
---|---|---|
|
||
First | 75 mg orally twice daily | 75 mg/m2 orally twice daily |
Second | 50 mg orally twice daily | 50 mg/m2 orally twice daily |
Third | 100 mg orally once daily | 25 mg/m2 orally twice daily* |
Permanently discontinue VITRAKVI in patients who are unable to tolerate VITRAKVI after three dose modifications.
Dosage Modifications for Hepatotoxicity
The recommended dosage modifications for VITRAKVI liver function test abnormalities are provided in Table 2.
For CTCAE Grade 2 ALT and/or AST elevation, monitor liver function frequently as clinically indicated, to establish whether a dose interruption or reduction is required.
Severity* | Dosage Modification |
---|---|
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal | |
|
|
AST or ALT ≥ 5 × ULN with bilirubin ≤ 2 × ULN |
|
AST or ALT > 3 × ULN with total bilirubin > 2 × ULN in the absence of alternative causes |
|
Dosage Modifications for Coadministration with Strong CYP3A4 Inhibitors
Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the VITRAKVI dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inhibitor.
Dosage Modifications for Coadministration with Strong or Moderate CYP3A4 Inducers
Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. If coadministration of a strong CYP3A4 inducer cannot be avoided, double the VITRAKVI dose. Additionally, for coadministration with a moderate CYP3A4 inducer, double the VITRAKVI dose. After the inducer has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inducer.
Dosage Modifications for Patients with Hepatic Impairment
Reduce the starting dose of VITRAKVI by 50% in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment.
Administration
VITRAKVI capsule or oral solution may be used interchangeably.
Do not make up a missed dose within 6 hours of the next scheduled dose.
If vomiting occurs after taking a dose of VITRAKVI, take the next dose at the scheduled time.
Oral Solution packaged in one bottle containing 100 mL
- Store the glass bottle of VITRAKVI oral solution in the refrigerator. Discard any unused VITRAKVI oral solution remaining after 90 days of first opening the bottle.
- Prior to preparing an oral dose for administration, refer to the Instructions for Use.
Oral Solution packaged in two bottles each containing 50 mL
- Store the glass bottles of VITRAKVI oral solution in the refrigerator. Discard any unused VITRAKVI oral solution remaining after 31 days of first opening the bottle.
- Prior to preparing an oral dose for administration, refer to the Instructions for Use.
Frequently asked questions
More about Vitrakvi (larotrectinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (1)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Trexall
Trexall is used for acute lymphoblastic leukemia, acute lymphocytic leukemia, breast cancer ...
Selpercatinib
Selpercatinib systemic is used for non small cell lung cancer, solid tumors, thyroid cancer
Dabrafenib
Dabrafenib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Trametinib
Trametinib systemic is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.